Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigiousGold Medal by EcoVadis, the world's most trusted provider of business sustainability ratings. The com...
Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successfu...
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
* Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) * NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irr...
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2
Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025
/PRNewswire/ --Alveolus Bio
Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH
RAICHUR, India , March 12, 2025 /PRNewswire/ -- Shilpa Medicare Limited
Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%
RAICHUR, India, Aug. 28, 2024 /PRNewswire/ -- In a major breakthrough, Shilpa
Medicare Limited
